White Papers

2027-2028 GLP-1 Investment Guide

09/09/2026

As GLP-1 costs climb and pressure mounts to make a coverage decision, Omada's 2027-2028 GLP-1 Investment Guide offers benefit leaders new metrics for evaluating obesity care strategy, grounded in.

Beyond Stigma and Scripts: What the System Gets Wrong About Obesity Care

05/07/2026

In one of the largest surveys of its kind, Omada polled more than 3,000 people who have used GLP‑1s for weight loss, offering a timely view of how the GLP‑1 experience is evolving and where the.

Optimizing The Quantity and Quality of GLP-1 Weight Loss: Evidence from a 12-Week Comparative Study

04/10/2026

GLP‑1 medications have changed what’s possible for weight loss, but they also raise a critical question: what are people losing—fat, lean mass, or both? Omada’s Insights Lab conducted a 12‑week.

Webinars & Events

ADA State of Diabetes 2026 Partner

10/14/2026

Omada is proud to sponsor the American Diabetes Association® (ADA) State of Diabetes 2026 annual event in Chicago. This event brings employers, health plan leaders, and local advocates together for.

Beyond the Coverage Question: A New Playbook for Cardiometabolic Care

10/05/2026

Many 2027 benefits conversations about GLP-1s are still stuck on the “cover or don’t cover” question, and many cardiometabolic care conversations remain focused on individual conditions, rather than.

Beyond Point Solutions: Multi-Condition Support for Total Cost of Care

09/10/2026

Health plans are being asked to solve for total cost of care across a growing set of overlapping conditions — obesity, diabetes, hypertension, cholesterol, and multi-condition members at the.

Keep Browsing

See All Posts
Become an Omada Insider
Sign Up